Fabio Cataldi

Statistics

Publications

Citations

1.3K

H-Index

Active since

1997

Affiliations

Pfizer (United States)(Current)

University of California San Diego

Christian-Albrechts-Universität zu Kiel

University of Lübeck

Medical University of Vienna

Fabio Cataldi is an author at Pfizer (United States) specializing in inflammatory bowel disease therapy, inflammatory bowel disease, and gastrointestinal inflammation.

Publications per year

1997–2025

Publications

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

William J. Sandborn, Séverine Vermeire, Laurent Peyrin‐Biroulet et al. · The Lancet · 2023 · 333 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +17

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

Séverine Vermeire, William J. Sandborn, Silvio Danese et al. · The Lancet · 2017 · 197 citations

Life Sciences, Immunology, Pharmacotherapy +14

Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study

Walter Reinisch, Julián Panés, Sunil Khurana et al. · Gut · 2015 · 153 citations

Life Sciences, Immunology, Pharmacology +17

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study

William J. Sandborn, Scott D. Lee, Dino Tarabar et al. · Gut · 2017 · 107 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

A pharmacokinetic comparison of anrukinzumab, an anti‐ IL‐13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients

Fei Hua, Jakob Ribbing, Walter Reinisch et al. · British Journal of Clinical Pharmacology · 2015 · 47 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +11

1–5 of 25